{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:55:58Z","timestamp":1790798158739,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01701-w","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:33:18Z","timestamp":1790749998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimization of Cefotaxime Treatment in Intensive Care Patients: Impact of Inter- and Intra-patient Variability on Pharmacokinetics and Target Attainment"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3823-5672","authenticated-orcid":false,"given":"Anth\u00e9a","family":"Deschamps","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Gattacceca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Velly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Guilhaumou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1701_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/jac\/dkm460","volume":"61","author":"J Garnacho-Montero","year":"2007","unstructured":"Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabo-Pallas T, Cayuela-Dominguez A, Marquez-Vacaro JA, et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother. 2007;61:436\u201341. https:\/\/doi.org\/10.1093\/jac\/dkm460.","journal-title":"J Antimicrob Chemother"},{"key":"1701_CR2","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"J-L Vincent","year":"2009","unstructured":"Vincent J-L. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323. https:\/\/doi.org\/10.1001\/jama.2009.1754.","journal-title":"JAMA"},{"key":"1701_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/01.CCM.0000050298.59549.4A","volume":"31","author":"M Leone","year":"2003","unstructured":"Leone M, Bourgoin A, Cambon S, Dubuc M, Alban\u00e8se J, Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med. 2003;31:462\u20137. https:\/\/doi.org\/10.1097\/01.CCM.0000050298.59549.4A.","journal-title":"Crit Care Med"},{"key":"1701_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","volume":"34","author":"A Kumar","year":"2006","unstructured":"Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589\u201396. https:\/\/doi.org\/10.1097\/01.CCM.0000217961.75225.E9.","journal-title":"Crit Care Med"},{"key":"1701_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1378\/chest.122.1.262","volume":"122","author":"M Iregui","year":"2002","unstructured":"Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262\u20138. https:\/\/doi.org\/10.1378\/chest.122.1.262.","journal-title":"Chest"},{"key":"1701_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498\u2013509. https:\/\/doi.org\/10.1016\/S1473-3099(14)70036-2.","journal-title":"Lancet Infect Dis"},{"key":"1701_CR7","volume-title":"Antibioth\u00e9rapie probabiliste des \u00e9tats sceptiques graves: conf\u00e9rence d\u2019expert","author":"B Veber","year":"2004","unstructured":"Veber B, Soci\u00e9t\u00e9 de R\u00e9animation de Langue Fran\u00e7aise, Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et de R\u00e9animation. Antibioth\u00e9rapie probabiliste des \u00e9tats sceptiques graves: conf\u00e9rence d\u2019expert. Paris: Elsevier; 2004."},{"key":"1701_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2165\/00003495-199040040-00008","volume":"40","author":"PA Todd","year":"1990","unstructured":"Todd PA, Brogden RN. Cefotaxime: an update of its pharmacology and therapeutic use. Drugs. 1990;40:608\u201351. https:\/\/doi.org\/10.2165\/00003495-199040040-00008.","journal-title":"Drugs"},{"key":"1701_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13613-015-0093-5","volume":"5","author":"C Vinsonneau","year":"2015","unstructured":"Vinsonneau C, Allain-Launay E, Blayau C, Darmon M, du Cheyron D, Gaillot T, et al. Renal replacement therapy in adult and pediatric intensive care: recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD). Ann Intensive Care. 2015;5:58. https:\/\/doi.org\/10.1186\/s13613-015-0093-5.","journal-title":"Ann Intensive Care"},{"key":"1701_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/jac\/5.4.419","volume":"5","author":"PM Shah","year":"1979","unstructured":"Shah PM, Troche G, Stille W. Effect of concentration on bactericidal activity of cefotaxime. J Antimicrob Chemother. 1979;5:419\u201322. https:\/\/doi.org\/10.1093\/jac\/5.4.419.","journal-title":"J Antimicrob Chemother"},{"key":"1701_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.diagmicrobio.2003.09.010","volume":"48","author":"JF Mohr","year":"2004","unstructured":"Mohr JF, Wanger A, Rex JH. Pharmacokinetic\/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis. 2004;48:125\u201330. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2003.09.010.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1701_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1086\/514622","volume":"27","author":"JD Turnidge","year":"1998","unstructured":"Turnidge JD. The pharmacodynamics of \u03b2\u2010lactams. Clin Infect Dis. 1998;27:10\u201322. https:\/\/doi.org\/10.1086\/514622.","journal-title":"Clin Infect Dis"},{"key":"1701_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients: guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation\u2014SFAR). Crit Care. 2019;23:104. https:\/\/doi.org\/10.1186\/s13054-019-2378-9.","journal-title":"Crit Care"},{"key":"1701_CR14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2018","unstructured":"Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother. 2018;73:564\u20138. https:\/\/doi.org\/10.1093\/jac\/dkx427.","journal-title":"J Antimicrob Chemother"},{"key":"1701_CR15","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/cc9091","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone FS, Laterre P-F, Dugernier T, Spapen H, Delattre I, Witebolle X, et al. Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14:R126. https:\/\/doi.org\/10.1186\/cc9091.","journal-title":"Crit Care"},{"key":"1701_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00228-021-03218-6","volume":"78","author":"M Swartling","year":"2022","unstructured":"Swartling M, Smekal A-K, Furebring M, Lipcsey M, J\u00f6nsson S, Nielsen EI. Population pharmacokinetics of cefotaxime in intensive care patients. Eur J Clin Pharmacol. 2022;78:251\u20138. https:\/\/doi.org\/10.1007\/s00228-021-03218-6.","journal-title":"Eur J Clin Pharmacol"},{"key":"1701_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/bcp.15487","volume":"89","author":"EE Roelofsen","year":"2023","unstructured":"Roelofsen EE, Abdulla A, Muller AE, Endeman H, Gommers D, Dijkstra A, et al. Dose optimization of cefotaxime as pre\u2010emptive treatment in critically ill adult patients: a population pharmacokinetic study. Br J Clin Pharmacol. 2023;89:705\u201313. https:\/\/doi.org\/10.1111\/bcp.15487.","journal-title":"Br J Clin Pharmacol"},{"key":"1701_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0487-8","volume":"18","author":"J Koeze","year":"2017","unstructured":"Koeze J, Keus F, Dieperink W, Van Der Horst ICC, Zijlstra JG, Van Meurs M. Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria. BMC Nephrol. 2017;18:70. https:\/\/doi.org\/10.1186\/s12882-017-0487-8.","journal-title":"BMC Nephrol"},{"key":"1701_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12081289","volume":"12","author":"R Guilhaumou","year":"2023","unstructured":"Guilhaumou R, Chevrier C, Setti JL, Jouve E, Marsot A, Julian N, et al. \u03b2-Lactam pharmacokinetic\/pharmacodynamic target attainment in intensive care unit patients: a prospective, observational, cohort study. Antibiotics (Basel). 2023;12:1289. https:\/\/doi.org\/10.3390\/antibiotics12081289.","journal-title":"Antibiotics (Basel)"},{"key":"1701_CR20","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303\u201311.","journal-title":"Nutrition"},{"key":"1701_CR21","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"J-R Le Gall","year":"1993","unstructured":"Le Gall J-R. A new simplified acute physiology score (SAPS II) based on a European\/North American multicenter study. JAMA. 1993;270:2957. https:\/\/doi.org\/10.1001\/jama.1993.03510240069035.","journal-title":"JAMA"},{"key":"1701_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"J-L Vincent","year":"1996","unstructured":"Vincent J-L, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707\u201310. https:\/\/doi.org\/10.1007\/BF01709751.","journal-title":"Intensive Care Med"},{"key":"1701_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"1701_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.medmal.2016.01.010","volume":"46","author":"P Longuet","year":"2016","unstructured":"Longuet P, Lecapitaine AL, Cassard B, Batista R, Gauzit R, Lesprit P, et al. Preparing and administering injectable antibiotics: how to avoid playing God. Med Mal Infect. 2016;46:242\u201368. https:\/\/doi.org\/10.1016\/j.medmal.2016.01.010.","journal-title":"Med Mal Infect"},{"key":"1701_CR25","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 18 Aug 2020."},{"key":"1701_CR26","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1128\/AAC.00533-11","volume":"55","author":"M-C Verdier","year":"2011","unstructured":"Verdier M-C, Tribut O, Tattevin P, Le Tulzo Y, Michelet C, Bentu\u00e9-Ferrer D. Simultaneous determination of 12 \u03b2-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring. Antimicrob Agents Chemother. 2011;55:4873\u20139. https:\/\/doi.org\/10.1128\/AAC.00533-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"1701_CR27","unstructured":"R Foundation for Statistical Computing. R Core Team (2020). R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, Austria. Available from: https:\/\/www.R-project.org\/. Accessed 2 Sep 2026."},{"key":"1701_CR28","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan L, Fran\u00e7ois R, et al. Welcome to the Tidyverse. JOSS. 2019;4:1686. https:\/\/doi.org\/10.21105\/joss.01686.","journal-title":"JOSS"},{"key":"1701_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/BF03261932","volume":"51","author":"CMT Sherwin","year":"2012","unstructured":"Sherwin CMT, Kiang TKL, Spigarelli MG, Ensom MHH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51:573\u201390. https:\/\/doi.org\/10.1007\/BF03261932.","journal-title":"Clin Pharmacokinet"},{"key":"1701_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacomet Syst Pharmacol. 2013;2:e51. https:\/\/doi.org\/10.1038\/psp.2013.26.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1701_CR31","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1007\/s11095-011-0422-9","volume":"28","author":"CM Laffont","year":"2011","unstructured":"Laffont CM, Concordet D. A new exact test for the evaluation of population pharmacokinetic and\/or pharmacodynamic models using random projections. Pharm Res. 2011;28:1948\u201362. https:\/\/doi.org\/10.1007\/s11095-011-0422-9.","journal-title":"Pharm Res"},{"key":"1701_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.131","volume":"3","author":"RJ Keizer","year":"2015","unstructured":"Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JHM, et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3:e00131. https:\/\/doi.org\/10.1002\/prp2.131.","journal-title":"Pharmacol Res Perspect"},{"key":"1701_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504. https:\/\/doi.org\/10.1023\/A:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1701_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/psp4.12611","volume":"10","author":"DJ Irby","year":"2021","unstructured":"Irby DJ, Ibrahim ME, Dauki AM, Badawi MA, Illamola SM, Chen M, et al. Approaches to handling missing or \u201cproblematic\u201d pharmacology data: pharmacokinetics. CPT Pharmacomet Syst Pharmacol. 2021;10:291\u2013308. https:\/\/doi.org\/10.1002\/psp4.12611.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1701_CR35","unstructured":"Kuhn M, Jackson S, Cimentada J. corrr: Correlations in R. 2022."},{"key":"1701_CR36","volume-title":"An R companion to applied regression","author":"J Fox","year":"2019","unstructured":"Fox J, Weisberg S. An R companion to applied regression. 3rd ed. Thousand Oaks: Sage; 2019.","edition":"3"},{"key":"1701_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/B:JOPA.0000034404.86036.72","volume":"31","author":"J Ribbing","year":"2004","unstructured":"Ribbing J, Niclas JE. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn. 2004;31:109\u201334. https:\/\/doi.org\/10.1023\/B:JOPA.0000034404.86036.72.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1701_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10928-019-09635-6","volume":"46","author":"M Ahamadi","year":"2019","unstructured":"Ahamadi M, Largajolli A, Diderichsen PM, De Greef R, Kerbusch T, Witjes H, et al. Operating characteristics of stepwise covariate selection in pharmacometric modeling. J Pharmacokinet Pharmacodyn. 2019;46:273\u201385. https:\/\/doi.org\/10.1007\/s10928-019-09635-6.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1701_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9485-1","volume-title":"Pharmacokinetic\u2013pharmacodynamic modeling and simulation","author":"PL Bonate","year":"2011","unstructured":"Bonate PL. Pharmacokinetic\u2013pharmacodynamic modeling and simulation. 2nd ed. New York: Springer; 2011.","edition":"2"},{"key":"1701_CR40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2125.2004.02170.x","volume":"58","author":"U Wahlby","year":"2004","unstructured":"Wahlby U, Thomson AH, Milligan PA, Karlsson MO. Models for time-varying covariates in population pharmacokinetic\u2013pharmacodynamic analysis. Br J Clin Pharmacol. 2004;58:367\u201377. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02170.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1701_CR41","unstructured":"Katsube T, Khandelwal A, Harling K, Hooker A, Karlsson M. Evaluation of stepwise covariate model building combined with cross-validation. Abstracts of the Annual Meeting of the Population Approach Group in Europe; 2011; abstract no. 2111."},{"key":"1701_CR42","unstructured":"Mihaljevic F, Lavielle M, Chauvin J, Pinaud C. Rsmlx: R Speaks \u201cMonolix\u201d. 2023. Available from: https:\/\/cran.r-project.org\/web\/packages\/Rsmlx\/index.html. Accessed 31 Jan 2024."},{"key":"1701_CR43","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Recommandation de bonne pratique. Diagnostic de la d\u00e9nutrition de l\u2019enfant et de l\u2019adulte. M\u00e9thode recommandations pour la pratique clinique. Texte des recommandations. 2019. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2019-11\/reco277_recommandations_rbp_denutrition_cd_2019_11_13_v0.pdf. Accessed 2 Sept 2026."},{"key":"1701_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1128\/AAC.16.2.127","volume":"16","author":"R L\u00fcthy","year":"1979","unstructured":"L\u00fcthy R, M\u00fcnch R, Blaser J, Bhend H, Siegenthaler W. Human pharmacology of cefotaxime (HR 756), a new cephalosporin. Antimicrob Agents Chemother. 1979;16:127\u201333. https:\/\/doi.org\/10.1128\/AAC.16.2.127.","journal-title":"Antimicrob Agents Chemother"},{"key":"1701_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00276-21","volume":"60","author":"CG Giske","year":"2022","unstructured":"Giske CG, Turnidge J, Cant\u00f3n R, Kahlmeter G. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin Microbiol. 2022;60:e00276-21. https:\/\/doi.org\/10.1128\/jcm.00276-21.","journal-title":"J Clin Microbiol"},{"key":"1701_CR46","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkn522","volume":"63","author":"P Seguin","year":"2009","unstructured":"Seguin P, Verdier MC, Chanavaz C, Engrand C, Laviolle B, Donnio P-Y, et al. Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis. J Antimicrob Chemother. 2009;63:564\u20137. https:\/\/doi.org\/10.1093\/jac\/dkn522.","journal-title":"J Antimicrob Chemother"},{"key":"1701_CR47","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1093\/jac\/dkad300","volume":"78","author":"S Goutelle","year":"2023","unstructured":"Goutelle S, Jullien V, Bru J-P, Cattoir V, Gauzit R, Lesprit P, et al. Defining standard and high dosages for \u03b2-lactam agents administered by intermittent, prolonged or continuous infusion: a PK\/PD simulation study. J Antimicrob Chemother. 2023;78:2762\u20139. https:\/\/doi.org\/10.1093\/jac\/dkad300.","journal-title":"J Antimicrob Chemother"},{"key":"1701_CR48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","volume":"59","author":"SJF Hartman","year":"2020","unstructured":"Hartman SJF, Br\u00fcggemann RJ, Orri\u00ebns L, Dia N, Schreuder MF, de Wildt SN. Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature. Clin Pharmacokinet. 2020;59:173\u2013205. https:\/\/doi.org\/10.1007\/s40262-019-00813-w.","journal-title":"Clin Pharmacokinet"},{"key":"1701_CR49","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/ndt\/gfh707","volume":"20","author":"EAJ Hoste","year":"2005","unstructured":"Hoste EAJ, Damen J, Vanholder RC, Lameire NH, Delanghe JR, Van Den Hauwe K, et al. Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol Dial Transplant. 2005;20:747\u201353. https:\/\/doi.org\/10.1093\/ndt\/gfh707.","journal-title":"Nephrol Dial Transplant"},{"key":"1701_CR50","doi-asserted-by":"publisher","first-page":"R108","DOI":"10.1186\/cc12777","volume":"17","author":"G Bragadottir","year":"2013","unstructured":"Bragadottir G, Redfors B, Ricksten S-E. Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury: true GFR versus urinary creatinine clearance and estimating equations. Crit Care. 2013;17:R108. https:\/\/doi.org\/10.1186\/cc12777.","journal-title":"Crit Care"},{"key":"1701_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.accpm.2016.03.004","volume":"35","author":"C Ichai","year":"2016","unstructured":"Ichai C, Vinsonneau C, Souweine B, Armando F, Canet E, Clec\u2019h C, et al. Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies). Anaesth Crit Care Pain Med. 2016;35:151\u201365. https:\/\/doi.org\/10.1016\/j.accpm.2016.03.004.","journal-title":"Anaesth Crit Care Pain Med"},{"key":"1701_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0377-1237(08)80049-4","volume":"64","author":"S Joshi","year":"2008","unstructured":"Joshi S, Murari T, Narula A, Baliga K, Charan V. How robust are our methods of detecting impaired glomerular filtration rate in the intensive care unit? Med J Armed Forces India. 2008;64:111\u20134. https:\/\/doi.org\/10.1016\/S0377-1237(08)80049-4.","journal-title":"Med J Armed Forces India"},{"key":"1701_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17:204. https:\/\/doi.org\/10.1186\/cc11454.","journal-title":"Crit Care"},{"key":"1701_CR54","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"LA Stevens","year":"2006","unstructured":"Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473\u201383. https:\/\/doi.org\/10.1056\/NEJMra054415.","journal-title":"N Engl J Med"},{"key":"1701_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nupar.2011.01.001","volume":"25","author":"A Ait Hssain","year":"2011","unstructured":"Ait Hssain A, Souweine B, Cano NJ. Physiopathologie de la d\u00e9nutrition en r\u00e9animation. Nutr Clin Metab. 2011;25:29\u201335. https:\/\/doi.org\/10.1016\/j.nupar.2011.01.001.","journal-title":"Nutr Clin Metab"},{"key":"1701_CR56","unstructured":"Alexandre P. Diagnostic de la d\u00e9nutrition de l\u2019enfant et de l\u2019adulte: m\u00e9thode recommandations pour la pratique clinique. 2019. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2019-11\/reco277_recommandations_rbp_denutrition_cd_2019_11_13_v0.pdf. Accessed 2 Sep 2026."},{"issue":"4","key":"1701_CR57","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/gastro\/gow013","volume":"4","author":"S Bharadwaj","year":"2016","unstructured":"Bharadwaj S, Ginoya S, Tandon P, Gohel TD, Guirguis J, Vallabh H, et al. Malnutrition: laboratory markers vs nutritional assessment. Gastroenterol Rep. 2016;4(4):272\u201380. https:\/\/doi.org\/10.1093\/gastro\/gow013.","journal-title":"Gastroenterol Rep"},{"key":"1701_CR58","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/ndt\/gfh719","volume":"20","author":"AJW Branten","year":"2005","unstructured":"Branten AJW, Vervoort G, Wetzels JFM. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant. 2005;20:707\u201311. https:\/\/doi.org\/10.1093\/ndt\/gfh719.","journal-title":"Nephrol Dial Transplant"},{"key":"1701_CR59","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1146\/annurev.me.39.020188.002341","volume":"39","author":"AS Levey","year":"1988","unstructured":"Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med. 1988;39:465\u201390. https:\/\/doi.org\/10.1146\/annurev.me.39.020188.002341.","journal-title":"Annu Rev Med"},{"key":"1701_CR60","first-page":"126","volume":"23","author":"C G\u00fczel","year":"2019","unstructured":"G\u00fczel C, Ye\u015filta\u015f S, Da\u015fkaya H, Uysal H, S\u00fcmer I, T\u00fcrkay M. The effect of gender on acute kidney injury developing in the intensive care unit. Hippokratia. 2019;23:126\u201330.","journal-title":"Hippokratia"},{"key":"1701_CR61","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1016\/j.ekir.2021.10.006","volume":"6","author":"AC Van Der Burgh","year":"2021","unstructured":"Van Der Burgh AC, Rizopoulos D, Ikram MA, Hoorn EJ, Chaker L. Determinants of the evolution of kidney function with age. Kidney Int Rep. 2021;6:3054\u201363. https:\/\/doi.org\/10.1016\/j.ekir.2021.10.006.","journal-title":"Kidney Int Rep"},{"key":"1701_CR62","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s10620-016-4416-7","volume":"62","author":"JG O\u2019Leary","year":"2017","unstructured":"O\u2019Leary JG, Wong F, Reddy KR, Garcia-Tsao G, Kamath PS, Biggins SW, et al. Gender-specific differences in baseline, peak, and delta serum creatinine: the NACSELD experience. Dig Dis Sci. 2017;62:768\u201376. https:\/\/doi.org\/10.1007\/s10620-016-4416-7.","journal-title":"Dig Dis Sci"},{"key":"1701_CR63","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117-314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"key":"1701_CR64","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/ki.1985.101","volume":"27","author":"S Mark Moran","year":"1985","unstructured":"Mark Moran S, Myers BD. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int. 1985;27:928\u201337. https:\/\/doi.org\/10.1038\/ki.1985.101.","journal-title":"Kidney Int"},{"key":"1701_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2015.06.002","volume":"24","author":"FB Sime","year":"2015","unstructured":"Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Curr Opin Pharmacol. 2015;24:1\u20136. https:\/\/doi.org\/10.1016\/j.coph.2015.06.002.","journal-title":"Curr Opin Pharmacol"},{"key":"1701_CR66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1378\/chest.11-1671","volume":"142","author":"AA Udy","year":"2012","unstructured":"Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, et al. Subtherapeutic initial \u03b2-lactam concentrations in select critically ill patients. Chest. 2012;142:30\u20139. https:\/\/doi.org\/10.1378\/chest.11-1671.","journal-title":"Chest"},{"key":"1701_CR67","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1093\/jac\/dkac261","volume":"77","author":"AJ Fratoni","year":"2022","unstructured":"Fratoni AJ, Mah JW, Nicolau DP, Kuti JL. Imipenem\/cilastatin\/relebactam pharmacokinetics in critically ill patients with augmented renal clearance. J Antimicrob Chemother. 2022;77:2992\u20139. https:\/\/doi.org\/10.1093\/jac\/dkac261.","journal-title":"J Antimicrob Chemother"},{"key":"1701_CR68","first-page":"497","volume":"81","author":"M Beumier","year":"2015","unstructured":"Beumier M, Casu GS, Hites M, Wolff F, Cotton F, Vincent JL, et al. Elevated \u03b2-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015;81:497\u2013506.","journal-title":"Minerva Anestesiol"},{"key":"1701_CR69","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000185817","volume":"54","author":"J Pascual","year":"1990","unstructured":"Pascual J, Lia\u00f1o F, Ortu\u00f1o J. Cefotaxime-induced encephalopathy in an uremic patient. Nephron. 1990;54:92. https:\/\/doi.org\/10.1159\/000185817.","journal-title":"Nephron"},{"key":"1701_CR70","doi-asserted-by":"publisher","first-page":"S309","DOI":"10.1007\/BF01715770","volume":"19","author":"HC Neu","year":"1991","unstructured":"Neu HC. Cephalosporins: cefotaxime 10 years later, a major drug with continued use. Infection. 1991;19:S309\u201315. https:\/\/doi.org\/10.1007\/BF01715770.","journal-title":"Infection"},{"key":"1701_CR71","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/0002-9343(90)90326-9","volume":"88","author":"FR Fekety","year":"1990","unstructured":"Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med. 1990;88:S38-44. https:\/\/doi.org\/10.1016\/0002-9343(90)90326-9.","journal-title":"Am J Med"},{"key":"1701_CR72","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/jac\/dkad223","volume":"78","author":"R Pai Mangalore","year":"2023","unstructured":"Pai Mangalore R, Peel TN, Udy AA, Peleg AY. The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting. J Antimicrob Chemother. 2023;78:2395\u2013405. https:\/\/doi.org\/10.1093\/jac\/dkad223.","journal-title":"J Antimicrob Chemother"},{"key":"1701_CR73","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1681\/ASN.2008070669","volume":"20","author":"SS Waikar","year":"2009","unstructured":"Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol. 2009;20:672\u20139. https:\/\/doi.org\/10.1681\/ASN.2008070669.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01701-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01701-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01701-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:02:35Z","timestamp":1790794955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01701-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":73,"alternative-id":["1701"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01701-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anth\u00e9a Deschamps, Florence Gattacceca, Olivier Blin, Lionel Velly, and Romain Guilhaumou have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Intensive care unit patient data from a previous study were approved by the ethics committee \u201c\n                      Comit\u00e9 de Protection des Personnes Sud-Est I\n                      \u201d (Ref 2017-A01446-47).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data will be made available, on reasonable request.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Mxtran code is available as a supplementary file.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LV and RG contributed to the protocol development, study design and concept, data acquisition, and coordination. Model development and simulations were performed by AD under the supervision of FG and RG. Suggestions for model improvement were made by all authors. The first draft of the manuscript was written by AD and all authors contributed to intermediate versions of the manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}